Cell Culture Dish Podcast cover art

Cell Culture Dish Podcast

Cell Culture Dish Podcast

By: Brandy Sargent
Listen for free

This Season's Biggest Deal | $0.99/mo for 3 months + $20 Audible bonus

Auto-renews at $8.99/mo. after 3 months - terms apply.
Summary
The Cell Culture Dish (CCD) podcast covers areas important to the research, discovery, development, and manufacture of disease and biologic therapeutics. Key industry coverage areas include: drug discovery and development, stem cell research, cell and gene therapy, recombinant antibodies, vaccines, and emerging therapeutic modalities.Copyright 2025. All rights reserved. Biological Sciences Hygiene & Healthy Living Nature & Ecology Physical Illness & Disease Science
Episodes
  • Rethinking Buffer Management Through Integrated Downstream Processing
    Nov 18 2026
    Buffer preparation is one of those parts of downstream processing that has traditionally been treated as a given. Buffers must be prepared, stored, and available when the purification process needs them, and facilities have long been designed around that requirement. But as biomanufacturing has scaled up, the amount of space, equipment and labor devoted to buffer preparation has grown with it. That was the starting point for a recent podcast discussion with Sébastien Lefebvre, Vice President R&D at VERDOT, and Nainesh Shah, Senior Application Engineer at Asahi Kasei Bioprocess. The two companies collaborated on a study looking at what happens when inline buffer formulation is connected directly with chromatography, using Asahi Kasei Bioprocess’ MOTIV® Inline Buffer Formulation System together with VERDOT’s FlexiPro™ Chrom platform. The work is described in more detail in the white paper, Transform Downstream Processing with an Integrated Solution: Optimize Time, Space and Cost Using MOTIV® Inline Buffer Formulation with FlexiPro™ Chrom. For Lefebvre, the collaboration grew out of something he had seen firsthand while visiting a customer planning a new downstream processing facility. The chromatography equipment itself occupied only a relatively small portion of the installation. Buffer preparation required much more space and, just as importantly, much more manpower. That observation led to a broader question about whether buffer preparation and chromatography really needed to operate as separate activities. “The starting question was very simple,” Lefebvre said. “How can we do better by working together?” Buffer Demand Has Changed Shah pointed out that the role of buffer preparation has changed as biomanufacturing has grown. Earlier processes often relied on a relatively limited number of established buffers and smaller production batches. Today, he said, a single manufacturing batch can require 50,000 to 60,000 liters of buffer. Keeping up with that demand using a conventional approach can mean expanding tank farms, adding equipment and devoting more people to preparing, cleaning, testing and managing buffers. Inline formulation changes that equation. Instead of preparing every finished buffer in advance, facilities prepare concentrated stock solutions that can be blended into the required formulation when the process needs them. Shah described the shift as moving toward treating buffer generation more like a manufacturing utility. “It’s a game changer, and looking at it as a utility more makes sense,” he said. Lefebvre made an important distinction during the conversation. Inline formulation does not eliminate buffer preparation. Concentrated stock solutions still need to be made and stored. What changes is the complexity of that preparation. Rather than asking operators to prepare a series of finished buffers with the correct combinations of salts, buffering components and other ingredients, facilities can prepare simpler concentrates and let the system handle the final formulation. “The real benefit is not the elimination of the preparation but simplification,” Lefebvre said. “You move the complexity from manual preparation to an automated system.” That matters because buffer preparation has traditionally depended heavily on experienced operators. Even with well-trained staff, mistakes can happen, and they may not be caught until the buffer reaches quality control. By that point, correcting the problem can mean lost time, additional work and, in some cases, delays to the downstream process. Lefebvre sees advances in analytics and process control as a way to move more of that work into an automated and controlled environment. Letting Chromatography Drive Buffer Production The most interesting part of the collaboration comes from linking buffer formulation directly with chromatography. In the setup evaluated by VERDOT and Asahi Kasei Bioprocess, FlexiPro Chrom communicates the actual buffer demand to the MOTIV system in real time. Instead of preparing buffer based solely on a forecast of what the chromatography step is expected to use, the formulation system can respond to what the process is actually consuming. Shah sees that kind of interoperability as part of a broader change in bioprocessing. Manufacturers increasingly want to choose the equipment that works best for each part of the process, even when those systems come from different suppliers. The important thing is to make sure they can communicate. “They will buy the best and then make sure that they talk to each other,” Shah said. In this case, the systems communicate through OPC UA, allowing information to move between equipment from different suppliers in real time. Shah noted that the same principle can extend beyond this particular application. As more systems become connected, information from multiple skids can be brought into a central control environment rather than ...
    Show More Show Less
    35 mins
  • Integrating Cleavage, Deprotection, and TFF: How Asahi Kasei’s THESYS® Platform Is Reshaping Oligonucleotide Manufacturing
    Apr 16 2026
    As demand for DNA and RNA therapeutics continues to accelerate, manufacturers are under increasing pressure to improve efficiency, reduce risk, and scale production without expanding facility footprints. One emerging solution is the integration of traditionally separate downstream steps into a single automated platform. Asahi Kasei Bioprocess, has addressed this need with the THESYS® platform, a suite of oligonucleotide manufacturing technologies designed to streamline workflows from synthesis through downstream processing. In a recent podcast, Sagar Bhatt, Senior Project Engineer at Asahi Kasei Bioprocess America, discussed the development of an integrated system within the THESYS C&D/TFF system combines cleavage, deprotection (C&D), and tangential flow filtration (TFF), and why this shift represents a meaningful evolution in oligonucleotide manufacturing. Rethinking a Fragmented Workflow Historically, oligonucleotide production has relied on a series of disconnected unit operations. Cleavage, deprotection, ultrafiltration, and diafiltration are often performed across multiple systems, sometimes even in different rooms. “Cleavage and deprotection are often carried out using fairly basic setups… and in many cases, they still involve a lot of manual handling,” Sagar explained. “They also typically require additional equipment, like separate tanks, which adds complexity to the process.” This fragmented approach introduces several challenges. Material transfers between systems increase processing time and create opportunities for product loss. In addition, deprotection reactions, particularly for RNA, require careful thermal control due to heat generated during acid addition. “If the rate of the acid addition and resulting temperature rise are not controlled carefully, it can negatively impact the product… and damage product quality.” Facility constraints add another layer of complexity. Because oligonucleotide processing often involves flammable solvents, operations must occur in hazardous environments. However, traditional filtration systems are not typically designed for these conditions, forcing manufacturers to physically move material between areas. Recognizing these inefficiencies, Sagar and his team saw an opportunity to simplify. “By integrating these operations into a single physical equipment and related automation, we could potentially streamline the workflow, reduce handling steps, and significantly improve overall manufacturing efficiency.” From Concept to THESYS® Integration The idea of combining reaction-based and membrane-based processes might seem complex, but Bhatt emphasized that the separation of these steps is largely historical, not technical. “Cleavage and deprotection are reaction steps… whereas TFF is a membrane separation process,” he said. “Though there are different mechanisms involved, they can operate on the same product stream and can share the same fluid handling architecture if designed properly.” Within the THESYS® platform, this integration is enabled through automation and system design that bring multiple unit operations into a single, cohesive workflow. Advances such as closed-loop temperature control, precise dosing, and real-time pressure monitoring allow both reaction and filtration steps to be managed within one system boundary. Equally important was designing the platform for hazardous environments from the outset. “That eliminated the need for intermediate product transfers, which made this integration approach much more practical.” Engineering for Efficiency and Scale One of the most significant engineering challenges was balancing performance with practicality. “Designing the combined system to keep the footprint to a minimum while also taking operability and maintainability into consideration was one of the biggest challenges,” Sagar said. The team also focused on minimizing holdup volume, maximizing product recovery, and ensuring cleanability for GMP operations—all within a compact system design aligned with THESYS®’s broader focus on efficient, scalable manufacturing systems. The result is a platform that delivers efficiency gains primarily by eliminating transfers. “In traditional setups, the material moves between different systems and sometimes even between different rooms,” he explained. “Each transfer adds time, manual handling, and potential product loss.” By consolidating operations into a single THESYS-based system, manufacturers can complete processes sequentially without interruption, reducing both time and risk. Improvements in Safety and Process Control Beyond efficiency, integration significantly enhances safety and control. “Operators no longer need to move material between systems in solvent handling environments,” Sagar said. “Keeping everything inside one enclosed physical system significantly reduces exposure risk and handling errors.” From a control standpoint, a unified ...
    Show More Show Less
    21 mins
  • Advancing Closed-System Performance: How CPC’s MicroCNX® Connectors Enable Scalable Cell and Gene Therapy Manufacturing
    Dec 9 2025
    In this podcast, we spoke with Troy Ostreng, Senior Product Manager and David Burdge, Director of Cell and Gene Therapy at CPC about the development of the MicroCNX® aseptic micro-connectors and how they’re helping biopharma teams streamline closed-system operations for cell and gene therapies. What unfolded was a detailed and forward-looking conversation that touched on CPC’s 47-year legacy, the technical demands of advanced therapies, and the company’s plans to drive the future of automation and sterility in manufacturing. A Legacy That Positioned CPC for Today’s Advanced Therapy Boom When asked how CPC’s long history in biologics and hospital environments prepared the company for today’s cell and gene therapy landscape, David took us back to CPC’s roots. “CPC was founded in 1978, so that’s 47 years of innovation within connection technologies,” he said. “The first biologic was released in 1982, synthetic insulin, and we were there supporting the industry with open-format connectors on single-use bags.” From the early development of biologics through the shift to single-use and the rise of stainless-steel/single-use hybrid systems, CPC continuously evolved its connection technologies. They launched steam-through connectors as bioprocessing grew more complex, released their first aseptic connector in 2009, and introduced their first connector specifically targeted for the cell and gene therapy market in 2017. David explained how that history matters today: “Biologics has about a 35-year head start on advanced therapies. So the question becomes, what lessons can we transfer from biologics to cell and gene therapy as that industry grows at three to four times the rate biologics did in its first decade?” That perspective, combining biological manufacturing experience with the needs of new therapy modalities, forms the foundation for CPC’s MicroCNX platform. MicroCNX: The First Aseptic Connector Built for Small-Format Tubing As cell and gene therapy developers began scaling up manufacturing, they quickly discovered a problem: the connectors used for biologics were not designed for small-volume, patient-specific therapies. Troy described it plainly: “Several years ago, we started hearing rumblings that current connectors weren’t meeting what cell and gene therapy required.” CPC responded with a deep Voice of Customer (VOC) initiative, interviewing process engineers, operators, manufacturing leaders, and platform developers. Over and over, the same needs emerged. Operators wanted something simple. “Ease of use was the number one requirement,” Troy said. “Operators needed a product that was easy to use so they could make sterile connections in a short amount of time.” Processes demanded robustness. “Customers needed a connection they could trust—no contamination, no failures, no weak spots in the connection process,” he added. Small-volume precise applications required connectors actually designed for them. With autologous therapies, he noted, “We aren’t talking about 1,000 liters; we’re talking about 250 milliliters. And if there’s a mishap, that could mean the difference between life and death for a patient.” All of this laid the groundwork for MicroCNX, which became the first aseptic connector engineered for small-format tubing. The “Pinch-Click-Pull” Process: Sterility Meets Speed One of the standout features of MicroCNX is its elegantly simple pinch-click-pull operation. Troy explained how simplicity came directly from user feedback. “As operators walked us through their pain points, what they needed was clear: a connector they could learn immediately. So MicroCNX has a three-step process—pinch, click, pull. You can literally do it as fast as I say it.” He continued,“Once someone does it one time, they’re basically an expert. That ease of use dramatically reduces operator error.” For an industry where operator variability remains one of the biggest sources of risk and batch loss, eliminating complexity is critical. Cryogenic Challenges Call for Cryo-Rated Solutions As the conversation shifted to cryopreservation, a critical component of cell therapy manufacturing,Troy introduced the MicroCNX® ULT and MicroCNX® Nano variants. “These were really developed because therapies were being frozen to –150°C, even –190°C. You need a connector that can be frozen to those temperatures, thawed, and still be as robust as it was before.” The ULT and Nano were engineered with: Low-profile geometries to fit inside freezing cassettes Specialized materials to withstand thermal stress Chemical compatibility with DMSO and other cryoprotectants Enhanced durability to survive impacts while frozen Troy emphasized how critical it was to get the materials right: “We searched extensively for a material that could handle those harsh chemicals and temperatures. What we landed on was PPSU—polyphenylsulfone. It’s chemically sound, and it’...
    Show More Show Less
    33 mins
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.